Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure - Top-Institutions - MDSpire

Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure

  • By

  • Xiangyong Li

  • Baoer Wu

  • Huaping Xie

  • Hao Hu

  • Ting Liu

  • Xu You

  • Yanhua Bi

  • Yurong Gu

  • July 8, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    The Third Affiliated Hospital of Sun Yat-sen University
    The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong

    Key Differentiators

    • Hepatology

  • #2

    REVEAL-HBV study
    REVEAL-HBV study

    Taipei, Taiwan

    Key Differentiators

    • Hepatology

  • #3

    Hiroshima University Hospital
    Hiroshima University Hospital

    Hiroshima, Hiroshima

    Key Differentiators

    • Hepatology

Original Source(s)

Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure

  • by Xiangyong Li, Baoer Wu, Huaping Xie, Hao Hu, Ting Liu, Xu You, Yanhua Bi, Yurong Gu

  • July 8, 2026

Related Content

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting

Laparoscopic-assisted subtotal colectomy cecal-rectal anastomosis for redundant colon-associated slow-transit constipation: a single-center retrospective case series with long-term follow-up